Management of symptons associated with advanced cancer: olanzapine and mirtazapine

References

• ••
   Google Scholar
• Waller A, Caroline NL. Handbook of Palliative Care in Cancer (2nd Edition). Butterworth-Heinemann (2000).
   Google Scholar
• Davis MP, Dickerson ED. Olanzapine: another psychotropic? Am. j Hospice Palliative Care 18(2), 129–132 (2001).
   Google Scholar
• Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacological Rev 53(1), 119–133 (2001).
   PubMedGoogle Scholar
• •A major pharmacodynamic difference between typical and atypical antipsychotics is D2 and D3 receptor binding affinity. This article reviews the differences between the various antipsychotics.
   Google Scholar
• Moore NA, Leander JD, Benvenga MJ etal. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. Clin. Psychiatry 10,37–44 (1997).
   Google Scholar
• Stephenson CME, Pilowsky LS. Psychopharmacology of olanzapine: a review. Br. PTchiatry174(38S), 52–58 (1999).
   Google Scholar
• •A well written review on olanzapinepharmacology and clinical outcomes.
   Google Scholar
• Worrell JA, Marken PA, Beckman SE et al A typical antipsychotic agents: a critical review. Am. j Health Syst. Phatm. 57(3), 238–255 (2000).
   Google Scholar
• Raedler TJ, Knable B, Jones DW etal. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychophamacology 23(1), 56–68 (2000).
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Falcone JF, Bauzon D et al Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur. Phalmacol 430(2–3), 341–349 (2001).
   Google Scholar
• Callaghan JT, Bergstrom RF, Ptak LR etal. Olanzapine: Pharmacokinetic and pharmacodynamic profile. Clin. Phatmcokinet. 37(3),177-93 (1999).
   Google Scholar
• ••Summarizes the use of olanzapine inspecial populations (i.e., the elderly and those with renal and hepatic impairment). This article also reviews olanzapine drug interactions.
   Google Scholar
• Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur. Clin. Pharmacol. 54(8), 639–643 (1998).
   Google Scholar
• Hagg S, Spigset O, Lakso HA etal. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur. Clin. Pharmacol 57(6–7), 493–497 (2001).
   Google Scholar
• Melkersson K, Khan A, Hilding A et al. Different effects of antipsychotic drugs on insulin release in vitro. Eur. Neuropsychopharmacolll (5), 327–332 (2001).
   Google Scholar
• Melkersson KI, Hulting Al, Brismar KE. Elevated levels of insulin, leptin and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J. Clin. PTchiatry61 (10), 742–749 (2000).
   Google Scholar
• Stephenson CM, Pilowsky LS. Psychopharmacology of olanzapine. A review. BE J. Psychiatry (Suppl. 38), 52–58 (1999).
   Google Scholar
• Beasley CM, Tollefson G, Tran P et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology14(2), 111–123 (1996).
   PubMed Web of Science ®Google Scholar
• Sacristan JA, Gomez JC, Montejo AL et al. Doses of olanzapine, risperidone and haloperidol used in clinical practice: results of a prospective pharmaepidemiologic study. Clin. Ther 22(5), 583–599 (1999).
   Google Scholar
• Gilbody SM, Bagnall AM, Duggan L et al. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database Syst. Rev 3:CD002306 (2000).
   Google Scholar
• Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, pharmacokinetic efficacy. Ann. Pharmacother. 33(1), 73–85 (1999).
   Google Scholar
• Gomez JC, Sarcristan JA, Hernandez J et al. The safety of olanzapine compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO Study). Pharmacoepidemiologic Study of Olanzapine in Schizophrenia. J. Clin. PTchiatry61 (5), 335–43 (2000).
   Google Scholar
• Tran PV, Dellva MA, Tollefson GD et al Extrapyramidal symptoms and tolerability of olanzapine versushaloperidol in the acute treatment of schizophrenia. J. Clin. PTchiatry58(5), 205–211 (1997).
   Google Scholar
• Keck PE, Stakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility and suicidality in patients with schizophrenia. J. Clin. fiychiatry61 (3), 4–9 (2000).
   Google Scholar
• Beasley CM, Hamilton SH, Crawford AM et al Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7(2), 125–137 (1997).
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L et al Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr Res. 43(2-3), 135–143 (2000).
   Google Scholar
• Madhusoodanan S, Brenner R, Suresh P etal Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Ann. Clin. Psychiatry 12(1), 11–18 (2000).
   Google Scholar
• Kim KS, Pae CU, Chae JH et al. An open pilot trial of olanzapine for delirium in the Korean population. Psychiatry Clin. Neumsci. 55 (5), 515–519.
   Google Scholar
• Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics 39,422–430 (1998).
   PubMed Web of Science ®Google Scholar
• •This trial demonstrates the benefits of olanzapine in the management of delirium.
   Google Scholar
• Costa E Silva JA, Alvarez N, Mazzoti G etal Olanzapine as alternative therapy for patients with halperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America. J. Clin. PTchopharmcol 21 (4), 375–381 (2001).
   Google Scholar
• •This article provides evidence that olanzapine can be safely used in individuals who experience extrapyramidal symptoms with classical antipsychotics.
   Google Scholar
• Lundbert J, Passik S. Controlling opioid-induced nausea with olanzapine. Prim. Care Cancer 20,5–7 (2000).
   Google Scholar
• Sanford-Kiser R, Cohen HM, Freedenfeld RN etal Olanzapine for the treatment of fibromyalgia symptoms. J. Pain Sym. Man. 22(2), 704–708 (2001).
   Google Scholar
• Rozen TD. Olazapine as an abortive agent for cluster headache. Headache 41(8), 813–816 (2001).
   PubMedGoogle Scholar
• Beasley CM, Tollefson GD, Tran PV. Safety in olanzapine. j Clin. Psychiatry 58 (10), 13–17 (1997).
   Google Scholar
• Bhana N, Foster RII, Olney R et al Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 61(1), 111–161 (2001).
   PubMed Web of Science ®Google Scholar
• •This is the most extensive review of olanzapine available to date.
   Google Scholar
• Jarventausta K, Leinonen E. Neuroleptic malignant syndrome during olanzapine and levompromazine treatment. Acta Psychiatrica Scandinavica 102(3), 231–233 (2000).
   PubMed Web of Science ®Google Scholar
• Conely RR, Meltzer HY. Adverse events related to olanzapine. Adverse events related to olanzapine. j Clin. fiychiatry 61 (8), 26-29(2000).
   Google Scholar
• Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. j Clin. Psychiatry 23,30–38 (2001).
   Google Scholar
• Green B. Focus on olanzapine. CUI7: Med. Res. Opin. 15(2), 79–85 (1999).
   Google Scholar
• Czekalla J, Kollack—Walker S, Beasley CM Jr. Cardiac safety parameters of olanzapine: comparison with other atypical and typical antipsychotics. j Clin. PTchiatry 62 (2), 35–40 (2001).
   Google Scholar
• Foster RII, Goa KL. Olanzapine. A pharmacoeconomic review of it use in schizophrenia. Pharmacoeconomics 15 (6), 611–640 (1999).
   PubMedGoogle Scholar
• Puzantian T Mirtazapine, an antidepressant. Am. J. Health Syst Pharm. 55(1), 44–49 (1998).
   PubMedGoogle Scholar
• ••An excellent review of the pharmacologyand clinical efficacy of mirtazapine.
   Google Scholar
• Davis MP, Dickerson ED, Pappagallo M et al Mirtazapine: heir apparent to amitriptyline? Am J. Hospice Palliative Care 18(1), 42–46 (2001).
   PubMedGoogle Scholar
• Frazer A. Pharmacology of antidepressants. Clin. PTchophannacy17(2S), 1–36
   Google Scholar
• ••This review is a comprehensive referenceon comparisons of various antidepressants.
   Google Scholar
• de Boer TD. The pharmacologic profile of mirtazapine. j Clin. Psychiatry57(4), 19–25 (1996).
   Google Scholar
• Gorman JM. Mirtazapine: clinical overview. J. Clin. PTchiatry 60 (17), 9–13.
   Google Scholar
• •An excellent short and concise review of mirtazapine's unique characteristics.
   Google Scholar
• Burrows GD, Kremer CM. Mirtazapine: clinical advantages in the treatment of depression. J. Clin. Bychopharmacol 1, 34S-93 (1997).
   Google Scholar
• Blier P Possible neurobiological mechanisms underlying faster onset of antidepressant action. J. Clin. Psychiatry62(4), 7–11 (2001).
   Google Scholar
• •Though somewhat controversial, mirtazapine's antidepressant benefits appear to occur earlier compared with SSR1s. This article reviews the possible mechanisms for the rapid onset of mirtazapine's antidepressant benefit.
   Google Scholar
• Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. j Affective Disorders 51 (3), 267–285 (1998).
   PubMed Web of Science ®Google Scholar
• ••One of the best reviews on mirtazapine.
   Google Scholar
• Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin. Proc. 72(9), 835–847 (1997).
   Google Scholar
• ••For those who have trouble puttingtogether antidepressants and drug interactions related to hepatic cytochrome enzymology, this is an excellent reference.
   Google Scholar
• Timmer CJ, Sitsen JM, Delbressine LP Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinetics 38 (6), 461–474 (2000).
   PubMed Web of Science ®Google Scholar
• ••Another excellent synopsis of mirtazapinepharmacology.
   Google Scholar
• Delbressine LPC, Vos RME. The clinical relevance of preclinical data: mirtazapine, a model compound. j Clin. Psycopharmacol 17(25), 29S-33S (1997).
   Google Scholar
• Stormer E, von Moltke LL, Shader RI et al Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P450 1A2, 2D6 and 3A4. Drug Metabol Disp. 28(10), 1168–1175 (2000).
   Google Scholar
• Davis MP, Homsi J. The importance of cytochrome P450 monoxygenase CYP2D6 in palliative medicine. Support Care Cancer 9,442–451 (2001).
   PubMed Web of Science ®Google Scholar
• Anttila SA, Leinonen EV. A review of pharmacological and clinical profile of mirtazapine. CNS Drug-Rev. 7(3), 246–264 (2001).
   Google Scholar
• Stahl S, Zivkov M, Reimitz PE et al. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta PTchiatrica Scam 391,22–30 (1997).
   PubMedGoogle Scholar
• Guelfi JD, Ansseau M, Timmerman L et al Mirtazapine versus in hospitalized severely depressed patients with melancholic features. j Clin. PTchopharmacology21 (4), 425–431 (2001).
   Google Scholar
• Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int. Clin. PTchopharmacology13(2), 63–73 (1998).
   Google Scholar
• Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. j Clin. PTchopharmacology 17(2S), 19S-28S (1997).
   Google Scholar
• •Mirtazapine is as effective in severe depression as tricyclic antidepressants.
   Google Scholar
• Kasper S, Praschak-Rieder N, Tauscher J et al A risk-benefit assessment of mirtazapine in the treatment of depression. Drub Safety17 (4), 251–264 (1997).
   PubMedGoogle Scholar
• Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Database Abstracts Rev Effectiveness1,1–7 (2001).
   Google Scholar
• •This database review of 12 randomized control trials demonstrates mirtazapine's comparable efficacy to tricyclic antidepressants and earlier onset of antidepressant activity compared with SSR1s.
   Google Scholar
• Thase ME. Antidepressant treatment of the depressed patient with insomnia. j Clin. Psychiatry60(17), 28–31 (1999).
   Google Scholar
• Kast KE. Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy. Support Care Cancer9, 469–470 (2001).
   PubMed Web of Science ®Google Scholar
• Nutt DJ. Care of depressed patients with anxiety symptoms. j Clin. Psychiatry 60(17), 23–27 (1999).
   Google Scholar
• Thompson C. Mirtazapine versus selective serotonin re-uptake inhibitors. J. Clin. Psychiatry60(17), 18–22 (1999).
   Google Scholar
• Carpenter LL, Jocic Z, Hall JM et al Mirtazapine augmentation in the treatment of refractory depression. j Clin. Psychiatry 60(1), 45–49 (1999).
   Google Scholar
• •Demonstrates mirtazapine's ability to augment standard antidepressants in patients with refractory depression without risk or increasing side effects.
   Google Scholar
• Carpenter LL, Leon Z, Yasmin S et al Clinical experience with mirtazapine in the treatment of panic disorder. Ann. Clin. Psychiatry 11 (2), 6 (1999).
   Google Scholar
• Boshuisen ML, Slaap BR, Vester-Bloldand ED et al The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int. Clin. PTchopharmacology16(6), 363–368 (2001).
   Google Scholar
• Bruijn JA, Moleman P, Mulder PG et al Depressed in-patients respond differently to imipramine and mirtazapine. Pharmacopsychiatry32(3), 87–92 (1999).
   PubMedGoogle Scholar
• Riberio L, Busnello JV, Kauer-Sant'Anna M et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Brazilian J. Merl Biol. Res. 34(10), 1303–1307 (2001).
   Google Scholar
• Waldinger MD. Sexual side effects of antidepressants. Nederland's TijcIschrift voor Ceneeskuncle 143(37), 1853–1857 (1999).
   PubMedGoogle Scholar
• Koutouvidis N, Pratikakis M, Fotiadou A. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin re-uptake inhibitor treatment due to sexual dysfunction. Inter Clin. PTchopharmacology14(4), 253–255 (1999).
   Google Scholar
• Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Psychiatrica Scam 391,31–37 (1997).
   PubMedGoogle Scholar
• •A well-worth reading comparison of the different side effect profiles of mirtazapine, tricyclic antidepressants and SSR1s.
   Google Scholar
• Gelenberg AJ, Laukes C, McGahuey C et al Mirtazapine substitution in SSRI-induced sexual dysfuntion. j Clin. PTchiatry61 (5), 356–320 (2000).
   Google Scholar
• Waldinger MD, Berendsen I11 I, Schweitzer DH. Treatment of hot flashes with mirtazapine: four case reports. Matutitas 36(3), 165–168 (2000).
   Google Scholar
• Poyurovsky M, Weizman A. Mirtazapine for neuroleptic-induced akathisia. Am. j PTchiatry158(5), 819 (2001).
   PubMedGoogle Scholar
• Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. PTchosomatics 41(4), 356–359 (2000).
   PubMedGoogle Scholar
• •This case series of women with gynecological and breast cancers gives us a hint of the multiple symptom benefits of mirtazapine in cancer patients.
   Google Scholar
• Pedersen L, Klysner R. Antagonism of selective serotonin re-uptake inhibitor-induced nausea by mirtazapine. Inter Clin. PTchopharmacology12(1), 59–60 (1997).
   Google Scholar
• Hoes MJ, Zeijpveld JH. Mirtazapine as treatment for serotonin syndrome. Pharmacopsychiatry29(2), 81 (1996).
   PubMedGoogle Scholar
• Jung AC, Staiger T, Sullivan M. Review: selective serotonin re-uptake inhibitors are effective for mixed chronic pain. ACP Journal Club 128,3 (1998).
   Google Scholar
• Jung AC, Staiger T, Sullivan M. The efficacy of selective serotonin re-uptake inhibitors for the management of chronic pain. Database of Abstracts of Reviews of Effectiveness 1, 1–5 (2001).
   Google Scholar
• Brannon GE, Stone KD. The use of mirtazapine in a patient with chronic pain. J. Pain Symptom Management 18(5), 382–385 (1999).
   PubMed Web of Science ®Google Scholar
• Elliott AJ, Roy-Byrne PR Mirtazapine for depression in patients with human immunodeficiency virus. J. Gun. Psychwhalmacology20(2), 265–267 (2000).
   Google Scholar
• Egberts ACG, Lenderink AW, de Koning FHP et al Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment. J. Gun. Bychophatmacology 17(3), 149–155 (1997).
   Google Scholar
• Bremner JD, Wingard P, Walshe TA. Safety of mirtazapine in overdose. J. Clin. fiychiatry59(5), 233–235 (1998).
   Google Scholar
• Holm KJ, Jarvis B, Foster RII. Mirtazapine. A pharmacologic review of its use in depression. Phatmacoeconomics 17(5), 515–534 (2000).
   Google Scholar
• •A review of the economic advantage of mirtazapine despite its higher acquisition cost.
   Google Scholar
• Brown MC, Nimmerrichter AA, Guest JE Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. Eur. Psychiatry 14(4), 230–244 (1999).
   PubMedGoogle Scholar
• Sitsen JM, Mans FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug—drug interaction study in healthy male subjects. Eur j Clin. Pharmacol 56(5), 389–394 (2000).
   Google Scholar
• Sitsen J, Mans F, Timmer C. Drug—drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur. J. Drug Metabolism Phalmacokinetics 26(1–2), 109–121 (2001).
   Google Scholar
• Sitsen JM, Voortman G, Timmer CJ. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. PTchophatmacology14(2), 172–176 (2000).
   Google Scholar
• Konstantinidis A, Stastny J, Ptak-Butta J et al. Intravenous mirtazapine in the treatment of depressed in-patients. Eur Neumpsychopharmacology 12 (1), 57–50 (2002).
   PubMedGoogle Scholar